Verition Fund Management
RNAM

Verition Fund Management’s Avidity Biosciences RNAM Stock Holding History

Verition Fund Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73,800
Closed -$5.32M – 3334
2025
Q4 		$5.32M Buy
+73,800
New +$4.77M 0.02% 835

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Verition Fund Management's RNAM Position: Q1 2026 in Review

Verition Fund Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 680,721 shares — an estimated $49.1M sold.

Verition Fund Management first reported a position in RNAM in Q2 2023 and held it in 8 quarters. The position peaked at $49.1M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Verition Fund Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 680,721 Avidity Biosciences shares in Q1 2026, an estimated $49.1M.
  • Verition Fund Management first reported a position in Avidity Biosciences in Q2 2023 and held it in 8 quarters.
  • Verition Fund Management's Avidity Biosciences position peaked at $49.1M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.